To enhance the efficacy of cellular
immunotherapy for
gliomas, we tested the concept of using proinflammatory
cytokine treatment with
interferon-gamma (IFN-gamma) or
interleukin-1beta (IL-1beta) or both to render
glioma cells more susceptible to cytolysis by alloreactive cytotoxic T lymphocytes (aCTL). The
cytokines, separately or in combination, were able to upregulate major histocompatibility complex (MHC)
class I antigen or
intercellular adhesion molecule-1 (ICAM-1) on Fischer rat 9L
gliosarcoma cells. 9L cells were incubated in vitro for 24, 48, or 72 h with varying concentrations of rat IFN-gamma (0-2000 U/ml) or recombinant human
IL-1 (rHUIL-1) (0-1000 U/ml) or both. By 48 h, IFN-gamma (500 U/ml) maximally induced the percentage of positive expressing cells and the relative
antigen density of MHC class I and
ICAM-1 on 9L cells, whereas
IL-1 induced only
ICAM-1 expression. Simultaneous incubation of
IL-1 with IFN-gamma did not further affect the induction of class I on 9L cells more than that achieved with IFN-gamma alone. 9L cells with upregulated MHC class I and
ICAM-1 expression were more sensitive to lysis by aCTL in in vitro cytotoxicity assays, regardless of whether the precursor aCTL came from naive or from 9L-immunized rats. Furthermore, inhibition of 9L cytotoxicity in assays that included
blocking antibodies to MHC class I or to
ICAM-1 revealed that
T cell receptor (TCR) interactions with MHC class I and that
ICAM-1 interactions with lymphocyte function-associated-1 (LFA-1)
antigen account for a portion of the
glioma lysis by aCTL.